secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001628280-23-000381
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex names Brianna Gerber CFO effective Jan 1, 2023; salary $325K
----------------------------------------------------------------------

- Brianna Gerber appointed CFO after serving as interim CFO since August 2022.
- Base salary $325,000; discretionary target bonus 50% of base; LTI opportunity 70% of base (Black-Scholes).
- Termination w/o cause/good reason: 12-mo salary continuation, pro-rata bonus, COBRA (12 mos), accelerated vesting.
- CEO Fried highlights her role in shepherding ChromaDex to EBITDA positive business with fiscal responsibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023000381/0001628280-23-000381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023000381/cdxc-20230103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-000381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer